Abstract
Thirty one patients previously treated with surgery, radiation therapy and chemotherapy with a nitrosoureafor malignant supratentorial gliomas received a combination of carboplatin (CBDCA) and etoposide(VP16) at tumor progression. Carboplatin and etoposide(CE) were given, each at a dose of 100 mg/m2/day from day 1 to 3. The response was evaluated at each course and a minimum of three courses was required to definite stable patient.Tolerance was evaluated in 31 patients. None had renalor auditory toxicity. Side effects consisted of grade III hematologic toxicity in 6 patients (19%), and grade III hepatic toxicity in one patient. No gradeIV WHO toxicity was observed.All 31 patients could be evaluated for therapeutic response.A partial response was noted in 4 patients during 13, 34 +, 35 + and 51 + weeks. Ten patients had stabledisease after a minimum of 3 courses (19 to 37 weeks). The rate of partial response (PR)and stabilisation (S) was 45% (14/31). The median time to tumor progression (MTTP) for respondingand stable patients was 28 weeks. The median survival time(ST) for the entire group was 45 weeks and over 51 weeks for PR and S patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Walker MD, Green SB, Byar DP et al.: Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. New Engl J Med 303: 1323–1329, 1980
Feun LG, Wallace S, Stewart DJ, Chuang VP, Yung WKA, Leavens SE, Burgess MA, Savaraj N, Benjamin RS, Young SE, Tang RA, Handel S, Mavligit G, Fields WS: Intracarotid infusion of cis diamminedichloroplatinium in the treatment of recurrent malignant brain tumors. Cancer 54: 794–799, 1984
Poisson M, Pereon Y, Chiras J, Delattre JY: Treatment of recurrent malignant supratentorial gliomas with carboplatin (CBDCA). J Neuro Oncol 10: 139–144, 1991
Yung WKA, Mechtler L, Gleason MJ: Intravenous carboplatin for recurrent malignant glioma: A phase II study. Clin Onc 9: 860–864, 1991
Aisner J, Lee EJ: Etoposide current and future status. Cancer 67: 215–219, 1991
Boiardi A, Silvani A, Milanesi I, Botturi M, Broggi G: Primary glial tumor patients treated by combining cis-platin and etoposide. Neuro Onco 11: 165–170, 1991
Kovnar EH, Kellie SJ, Horowitz ME, Sanford RA, Langston JW, Mulhern RK, Jenkins JJ, Douglass EC, Etcubanas EE, Fairclough DL, Kun LE: Preirradiation cisplatin and etoposide in the treatment of high-risk medulloblastoma and other embryonal tumors of the central nervous system: A phase II study. Clin Onc 8: 330–336, 1990
Burger PC: Malignant astrocytic neoplasms: Classification, pathologic anatomy, and response to treatment. Semin in Oncology Vol 13 n1: 16–26, 1986
Rodriguez LA, Prados M, Silver P, Levin VA: Reevaluation of procarbazine for the treatment of recurrent malignant central nervous system tumors. Cancer 64: 2420–2423, 1989
Jeremic B, Grujicic D, Jevremovic S, Stanisavljevic B, Milojevic L, Ljubodrag D, Mijatovic L: Carboplatin and etoposide chemotherapy regimen for recurrent malignant glioma: a phase II study. J Clin Onc 10: 1074–1077, 1992
Newton HB, Junck L, Bromberg J, Page MA, Greenberg HS: Procarbazine chemotherapy in the treatment of recurrent malignant astrocytomas after radiation and nitrosourea failure. Neurology 40: 1743–1746, 1990
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ameri, A., Poisson, M., Chauveinc, L. et al. Treatment of recurrent malignant supratentorial gliomas with the association of carboplatin and etoposide: a phase II study. J Neurooncol 32, 155–160 (1997). https://doi.org/10.1023/A:1005784425680
Issue Date:
DOI: https://doi.org/10.1023/A:1005784425680